利妥昔单抗单药治疗后原发性肺黏膜相关淋巴组织淋巴瘤长期完全缓解。
Prolonged complete remission in a primary MALT lymphoma of the lung after rituximab monotherapy.
作者信息
Diamantidis M D, Chatzileontiadou S, Pantelidou D, Papaioannou M
机构信息
Division of Hematology, 1 Department of Internal Medicine, Aristotle University of Thessaloniki (AUTH), AHEPA General Hospital, Thessaloniki, Greece.
出版信息
Hippokratia. 2017 Apr-Jun;21(2):108-110.
BACKGROUND
Primary pulmonary non-Hodgkin lymphoma (NHL) is a rare entity. Despite its favorable prognosis, an optimal treatment approach has not been established until today, as there are few debated heterogeneous data in the literature. Many therapeutic options such as surgery, radiotherapy, chemotherapy alone or in combination, immunotherapy and/or immunochemotherapy all with similar results, have been reported.
CASE DESCRIPTION
We report the case of a 68-year-old man diagnosed with a primary marginal zone B-cell pulmonary NHL, with a durable complete response to rituximab monotherapy.
CONCLUSION
We support the therapeutic application of rituximab monotherapy as an attractive option for this malignancy. This effective approach exhibits significant antitumor activity leading to long-term complete remission and minimal hematological toxicity in contrast to other intensive chemotherapies and/or radiotherapy, which might have serious side effects. HIPPOKRATIA 2017, 21(2): 108-110.
背景
原发性肺非霍奇金淋巴瘤（NHL）是一种罕见疾病。尽管其预后良好，但由于文献中存在争议的异质性数据较少，至今尚未确立最佳治疗方法。已报道了许多治疗选择，如手术、放疗、单纯化疗或联合化疗、免疫疗法和/或免疫化疗，所有这些治疗方法的效果相似。
病例描述
我们报告了一例68岁男性，诊断为原发性边缘区B细胞肺NHL，对利妥昔单抗单药治疗有持久的完全缓解。
结论
我们支持将利妥昔单抗单药治疗作为这种恶性肿瘤的一种有吸引力的治疗选择。与其他可能有严重副作用的强化化疗和/或放疗相比，这种有效方法具有显著的抗肿瘤活性，可导致长期完全缓解且血液学毒性最小。《希波克拉底》2017年，21(2): 108 - 110。
Zotero 插件